Excel Industries Ltd
Excel Industries is engaged in manufacturing and selling of Chemicals, Pharma intermediates and Environmental products. [1]
- Market Cap ₹ 1,423 Cr.
- Current Price ₹ 1,132
- High / Low ₹ 1,760 / 798
- Stock P/E 16.2
- Book Value ₹ 1,264
- Dividend Yield 1.21 %
- ROCE 7.11 %
- ROE 5.21 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Stock is trading at 0.90 times its book value
- Company has been maintaining a healthy dividend payout of 26.2%
Cons
- The company has delivered a poor sales growth of 6.84% over past five years.
- Company has a low return on equity of 4.26% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 416 | 482 | 448 | 462 | 599 | 825 | 702 | 749 | 1,178 | 1,090 | 826 | 978 | 1,023 | |
| 376 | 409 | 385 | 419 | 474 | 574 | 571 | 628 | 946 | 961 | 801 | 857 | 900 | |
| Operating Profit | 40 | 72 | 63 | 44 | 125 | 250 | 131 | 122 | 232 | 129 | 25 | 121 | 123 | 
| OPM % | 10% | 15% | 14% | 9% | 21% | 30% | 19% | 16% | 20% | 12% | 3% | 12% | 12% | 
| 5 | 7 | 3 | 9 | 4 | 5 | 10 | 9 | 15 | 12 | 32 | 29 | 31 | |
| Interest | 12 | 14 | 13 | 11 | 7 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 
| Depreciation | 11 | 15 | 15 | 14 | 15 | 18 | 23 | 27 | 31 | 31 | 31 | 34 | 35 | 
| Profit before tax | 21 | 51 | 38 | 27 | 107 | 234 | 115 | 101 | 213 | 106 | 23 | 113 | 116 | 
| Tax % | 15% | 19% | 31% | 26% | 31% | 34% | 16% | 29% | 24% | 24% | 25% | 24% | |
| 18 | 41 | 26 | 20 | 74 | 153 | 96 | 71 | 161 | 80 | 17 | 85 | 88 | |
| EPS in Rs | 16.50 | 34.59 | 20.18 | 15.93 | 58.78 | 122.07 | 76.42 | 56.55 | 128.23 | 63.59 | 13.53 | 67.86 | 70.04 | 
| Dividend Payout % | 23% | 20% | 22% | 38% | 21% | 15% | 13% | 20% | 18% | 18% | 41% | 20% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% | 
| 5 Years: | 7% | 
| 3 Years: | -6% | 
| TTM: | 17% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% | 
| 5 Years: | -4% | 
| 3 Years: | -21% | 
| TTM: | 109% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% | 
| 5 Years: | 5% | 
| 3 Years: | -1% | 
| 1 Year: | -25% | 
| Return on Equity | |
|---|---|
| 10 Years: | 10% | 
| 5 Years: | 7% | 
| 3 Years: | 4% | 
| Last Year: | 5% | 
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 
| Reserves | 147 | 180 | 204 | 404 | 526 | 693 | 695 | 845 | 1,143 | 1,235 | 1,421 | 1,582 | 
| 102 | 95 | 89 | 68 | 10 | 7 | 24 | 9 | 7 | 3 | 2 | 12 | |
| 97 | 106 | 121 | 141 | 186 | 209 | 212 | 251 | 330 | 248 | 367 | 319 | |
| Total Liabilities | 352 | 387 | 421 | 619 | 728 | 916 | 937 | 1,111 | 1,487 | 1,493 | 1,795 | 1,920 | 
| 128 | 158 | 164 | 183 | 203 | 238 | 376 | 389 | 427 | 428 | 428 | 459 | |
| CWIP | 20 | 3 | 3 | 8 | 23 | 12 | 10 | 17 | 21 | 19 | 19 | 13 | 
| Investments | 22 | 23 | 27 | 211 | 282 | 394 | 264 | 365 | 547 | 625 | 984 | 1,085 | 
| 181 | 204 | 227 | 216 | 220 | 272 | 287 | 340 | 492 | 421 | 365 | 364 | |
| Total Assets | 352 | 387 | 421 | 619 | 728 | 916 | 937 | 1,111 | 1,487 | 1,493 | 1,795 | 1,920 | 
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | 44 | 46 | 31 | 119 | 135 | 110 | 91 | 109 | 125 | 72 | 62 | |
| -32 | -27 | -27 | 16 | -45 | -111 | -61 | -53 | -104 | -118 | -51 | -41 | |
| 20 | -23 | -17 | -48 | -73 | -24 | -31 | -17 | -17 | -35 | -17 | -16 | |
| Net Cash Flow | 1 | -6 | 1 | -1 | 1 | -0 | 17 | 21 | -12 | -27 | 4 | 4 | 
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 89 | 80 | 103 | 95 | 76 | 70 | 78 | 84 | 62 | 52 | 82 | 81 | 
| Inventory Days | 74 | 103 | 99 | 86 | 79 | 75 | 90 | 71 | 103 | 78 | 80 | 70 | 
| Days Payable | 81 | 84 | 112 | 98 | 123 | 108 | 122 | 126 | 112 | 64 | 139 | 102 | 
| Cash Conversion Cycle | 82 | 99 | 90 | 83 | 32 | 36 | 46 | 29 | 52 | 67 | 23 | 49 | 
| Working Capital Days | 17 | 28 | 27 | 42 | 50 | 57 | 49 | 51 | 61 | 61 | 47 | 58 | 
| ROCE % | 15% | 24% | 18% | 10% | 22% | 38% | 17% | 13% | 21% | 9% | 2% | 7% | 
Documents
Announcements
- 
        
          Board Meeting Intimation for Notice Of Board Meeting - Regulation 29(1) Of SEBI (LODR) Regulations, 2015
          
            24 Oct - Board meeting 11 Nov 2025 to approve unaudited results for quarter and half ended 30 Sep 2025; trading window closed.
- Closure of Trading Window 24 Oct
- 
        
          Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
          
            9 Oct - Certificate under Regulation 74(5) of SEBI ( Depositories and Participants) Regulations, 2018 from our Registrar and Transfer agents, MUFG Intime India Pvt Ltd is enclosed …
- 
        
          Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
          
            29 Sep - SCN from Principal Commissioner CGST Audit-III Mumbai demanding Rs4,06,11,539 for 2019-20 to 2022-23.
- 
        
          Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
          
            26 Sep - Received GST SCN demanding Rs.2,91,51,023 for 2019-20 to 2022-23; company denies merit.
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from bse
- 
    
      Financial Year 2011
      from bse
Concalls
- 
      Aug 2025TranscriptNotesPPT
- 
      May 2025Transcript PPT
- 
      Feb 2025TranscriptNotesPPT
- 
      Nov 2024TranscriptNotesPPT
- 
      Aug 2024TranscriptNotesPPT
- 
      May 2024TranscriptNotesPPT
- 
      Feb 2024TranscriptNotesPPT
- 
      Nov 2023TranscriptNotesPPT
- 
      Aug 2023TranscriptNotesPPT
- 
      Aug 2023TranscriptNotesPPT
- 
      May 2023TranscriptNotesPPT
- 
      Feb 2023TranscriptNotesPPT
- 
      Feb 2023TranscriptNotesPPT
- 
      Nov 2022TranscriptNotesPPT
Market Position
The company is the No. 1 Producer of DETC (Diethylthiophosphoryl Chloride) and one of the Top 5 Producers of Phosphonates in the world. [1]